Quantcast

Typhoid Fever – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Typhoid
Fever – Pipeline Review, H1 2019”
drug pipelines has been added
to ResearchAndMarkets.com’s offering.

Typhoid Fever – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Typhoid Fever (Infectious Disease), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of
key players involved in therapeutic development for Typhoid Fever and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase III, Phase II, Phase I,
Preclinical, Discovery and Unknown stages are 3, 1, 1, 7, 1 and 1
respectively. Similarly, the Universities portfolio in Phase II,
Preclinical and Unknown stages comprises 1, 1 and 1 molecules,
respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Typhoid Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Typhoid Fever
    (Infectious Disease) by companies and universities/research institutes
    based on information derived from company and industry-specific
    sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Typhoid Fever
    (Infectious Disease) therapeutics and enlists all their major and
    minor projects.
  • The pipeline guide evaluates Typhoid Fever (Infectious Disease)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Typhoid Fever (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Typhoid Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Typhoid Fever (Infectious Disease) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

  • Oct 08, 2012: Typhim Vi – Typhoid Polysaccharide Vaccine – antigen
    levels below required specification
  • Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of
    Typhoid Fever Vaccine
  • Jun 23, 2011: Sanofi Pasteur’s Typhim Vi Receives Prequalification
    From World Health Organization
  • Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of
    Oral Typhoid Vaccine Candidate
  • Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical
    Study Results for Typhoid Vaccine
  • Nov 21, 2005: Emergent BioSolutions Starts Clinical Study Of
    Single-Dose Oral Typhoid Vaccine
  • Aug 30, 2005: Emergent BioSolutions’ Typhoid Vaccine Achieves Positive
    Results In Phase II Clinical Study
  • Nov 29, 1994: Food And Drug Administration Grants License For A New
    Typhoid Fever Vaccine

Companies Mentioned

  • Eubiologics Co. Ltd.
  • GlaxoSmithKline PLC
  • Indian Immunologicals Ltd.
  • Ology Bioservices Inc.
  • Prokarium Ltd.
  • Protein Potential LLC
  • Sanofi Pasteur S.A.
  • Shantha Biotechnics Pvt. Ltd.
  • Walvax Biotechnology Co. Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u8b5z8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.